Opinion

Fred G. v. Anthem Blue Cross Life and Health Insurance Company

Court
District Court, C.D. California
Filed
Jul 7, 2025
Cited by
0 cases
Authority
More cited than 37.3%

The opinion

1

2

3

4

5

6

7

8 UNITED STATES DISTRICT COURT

9 CENTRAL DISTRICT OF CALIFORNIA

10

11 FRED G., Case No. 2:22-cv-05710-FLA (Ex)

12 Plaintiff,

MEMORANDUM OF DECISION

13 v. FOLLOWING BENCH TRIAL

14

ANTHEM BLUE CROSS LIFE AND

15 HEALTH INSURANCE CO., et al.,

16 Defendants.

17

18

19

20

21

22

23

24

25

26

27

28

1 This action arises from the denial of a request for benefits under a tax-exempt,

2 multi-employer health plan (the “Plan”), governed by the Employee Retirement

3 Income Security Act of 1974, 29 U.S.C. § 1001, et seq. (“ERISA”). Plaintiff Fred G.

4 (“Plaintiff”) brings claims against Defendant Director’s Guild of America-Producer

5 Health Plan (“Defendant” or “DGA”)1 for: (1) recovery of benefits due under an

6 ERISA benefit plan, pursuant to 29 U.S.C. § 1132(a)(1)(B) (“§ 1132(a)(1)(B)”);2 and

7 (2) breach of fiduciary duty under § 1132(a)(3). Dkt. 13.

8 This matter came to bench trial on December 6, 2024.3 Dkt. 101. After

9 evaluating the evidence and considering the parties’ arguments, the court issues the

10 following findings of fact and conclusions of law,4 pursuant to Fed. R. Civ. P. 52(a).

11 FINDINGS OF FACT

12 I. The Plan

13 The Plan provides medical benefits for its participants and their covered

14 dependents. DGA_FG 001400.5 The Plan documents consist of the DGA-Producer

15 Pension and Health Plans Health Trust Agreement (“Trust Agreement,” id. at 001239–

16 94) and Summary Plan Description (“SPD,” id. at 001295–431). Plaintiff is a Plan

17

18

1 Plaintiff originally brought this action against DGA and former Defendant Anthem

19 Blue Cross Life and Health Insurance Company (“Anthem”). Dkt. 1. On September

17, 2024, Anthem was dismissed from the action with prejudice pursuant to the

20

parties’ Notice of Settlement. Dkt. 88.

21

2 29 U.S.C. § 1132 is also commonly referred to as ERISA § 502.

22

3 In the Ninth Circuit, actions to recover benefits under ERISA are adjudicated by

23 bench trial. Kearney v. Standard Ins. Co., 175 F.3d 1084, 1095 (9th Cir. 1999).

24 4 The court’s characterization of its determinations as a “finding of fact” or

“conclusion of law” is not controlling. To the extent a determination is characterized

25 as “conclusion of law” but is more properly characterized as a “finding of fact,” or

26 vice versa, substance shall prevail over form.

5 Citations to “DGA_FG” refer to the Plan’s administrative record, which was lodged

27

as Dkts. 46-1 and 65-1. Citations to “ANTHEM_FREDG” refer to Anthem’s

28 administrative record, which was lodged as Dkts. 47-1 through 47-12.

1 participant, and his son, J.G., is a beneficiary. Id. at 000001.

2 The Plan covers mental health and substance abuse services, including intensive

3 outpatient and residential treatments for substance abuse or mental health. Id. at

4 001360. All care (aside from covered preventive care services which are not at issue

5 here) must be “Medically Necessary,” as the term is defined in the Plan documents.

6 Id. at 001355. As relevant here:

7 A treatment, service or supply is Medically Necessary when it is:

8  Consistent with generally accepted medical practice within the

medical community for the diagnosis or direct care of symptoms,

9

Sickness or injury of the patient, … where and at the time the

10 treatment, service or supply is rendered (the determination of

“generally accepted medical practice” is the prerogative of the

11

Health Plan through consultation with appropriate authoritative

12 medical … practitioners);

13  Ordered by the attending licensed Physician…, and not solely for

[the participant or beneficiary’s] convenience, [his or her]

14

Physician, Hospital or other health care provider;

15

 Consistent with professionally recognized standards of care in the

16 medical community with respect to the quality, frequency and

duration; and

17

 The most appropriate and Cost-Efficient treatment, service or

18 supply that can be safely provided, at the most Cost-Efficient and

19 medically appropriate site and level of service.

20 Id. at 001415–16 (errors in original). Additionally, “[a] medical or dental service or

21 supply will be considered Cost-Efficient if it is no more costly than any alternative

22 appropriate service or supply when considered in relation to all health care expenses

23 incurred in connection with the service or supply.” Id. at 001412.

24 The Trust Agreement provides, in relevant part:

25 The Plan Trustees [the “Trustees”] shall have the sole complete and

26 discretionary authority [to] … (2) grant or deny, in whole or in part,

particular claims for benefits filed by participants or beneficiaries, in

27 accordance with the Plan Trustees’ interpretation of the Health Plan

28 and their fact findings relative to any such claims for benefits, (3)

1 gberannetf iocri adreiensy, cino vaecrcaogred aton cpee wrsiotnhs t hcela Pimlainn gT rtou sbteee psa’ ritnicteiprparnettsa otiro n of

2 the Health Plan and their fact findings relative to any such claim for

coverage, … (5) determine the type and duration of any benefits

3

payable to any participant or beneficiary, in accordance with the Plan

4 Trustees’ interpretation of the Health Plan and their fact findings

relative to any dispute over the type or duration of benefits payable,

5

(6) make any and all other findings of fact, construction,

6 interpretations and decisions relative to the Health Plan, and relative

to other rights, if any, of all persons, participants or beneficiaries to

7

benefits or coverage, and (7) construe and/or interpret any provisions

8 of the Health Plan. No Producer or group of Producers, the Guild,

any insurance company or any other person, … or other entity shall

9

have the authority to exercise any of the powers described in this

10 subsection. …

11 Id. at 001261–62.

12 The Trustees are jointly responsible for interpreting Plan provisions and

13 establishing rules and regulations governing entitlement of benefits and administration

14 of the Plan, id. at 001251–54, but may “allocate in writing fiduciary and non-fiduciary

15 responsibilities or duties among Trustees, including the allocation and delegation of

16 such responsibilities to committees and subcommittees of the Board[.]” Id. at 001263.

17 The Trust Agreement further authorizes the Trustees to “establish such committees as

18 they in their discretion deem proper and desirable for the proper administration of the

19 Health Plan and Health Fund,” and establishes the Benefits Committee as a standing

20 committee with the authority and responsibility for, inter alia, “[a]pproving benefit

21 awards, and hearing and determining claims appeals[.]” Id. at 001265–66.

22 “The general purpose of a committee is to study and debate issues that arise in

23 the administration of the Health Plan and the Health Fund and to make

24 recommendations thereon to the Board for action by the Board.” Id. at 001265.

25 “Notwithstanding this general limitation, the Board may, by resolution duly adopted,

26 allocate and delegate to a committee the authority to take final action in specified

27 areas; and in such instances the action of the committee shall have the same binding

28 effect as action by the full Board.” Id. At the bench trial, Defendant admitted there is

1 no evidence in the record to establish that the Board delegated to the Benefits

2 Committee the authority to take final action on approving benefit awards and hearing

3 and determining claims appeals, by a resolution duly adopted by the Board.

4 The Trust Agreement also authorizes the Trustees to “designate in writing

5 persons who are not Trustees to carry out fiduciary or non-fiduciary responsibilities or

6 duties of the Trustees[.]” Id. at 001263. Anthem was the designated claim

7 administrator for the residential treatment services at issue here. Id. at 000001. For

8 appeal administration, the Plan relies on third-party medical reviewers, such as the

9 Medical Review Institute of America (“MRI”), to make decisions related to benefits

10 determinations. Id.

11 II. J.G.’s History and Medical Treatment

12 J.G. was admitted to Outback Therapeutic Expeditions (“Outback”), an outdoor

13 behavioral health program, from February 17 to May 11, 2020. Id. at 000043. In a

14 Parent Questionnaire, his mother reported that J.G. began using nicotine at age 11 to

15 12 and used it almost daily prior to his admission to Outback. Id. at 000826. He also

16 began using marijuana at age 15 and used it two to four times per week. Id. His

17 mother further reported J.G. was “often aggressive at home,” would “break things,

18 yell, [and] cuss often,” was often angry and defensive, experienced mood swings

19 often, and was quick to anger without provocation. Id. at 000825.6

20

6 J.G.’s behavioral and treatment history are further detailed in the administrative

21

record. Most notably, Plaintiff reported J.G. began to exhibit aggressive and

22 hyperactive behavior, anger, frustration, depression, and anxiety after Plaintiff “went

through a very traumatic divorce process” when J.G. was nine years old. DGA_FG

23

000040. J.G.’s behavior “spiraled downward when he entered middle school in the

24 fall of 2015,” and only grew worse as he transitioned to high school, as he withdrew

further from his family and his oppositional defiance at home escalated. Id. at

25

000041–42. J.G.’s physical and verbal aggression further escalated during the fall and

26 winter of 2019, to the point that he “destroyed countless items in [their] home,”

“punched and kicked his closet doors until they were folded in half,” “destroyed lamps

27

and mirrors with his fists and by throwing other items at them,” “shattered [their] car

28

1 On March 25, 2020, J.G. underwent a comprehensive psychological evaluation

2 conducted by Abby Jenkins, Ph.D. (“Dr. Jenkins”), a licensed clinical psychologist.

3 Id. at 000786–804. Based on his history and test results, Dr. Jenkins diagnosed J.G.

4 with: (1) Attention-Deficit/Hyperactivity Disorder, Combined Presentation; (2)

5 Oppositional Defiant Disorder; (3) Unspecified Anxiety Disorder; (4) Cannabis Use

6 Disorder; (5) Parent-Child Relational Problem; and (6) Child Affected by Parental

7 Relationship Distress. Id. at 000801–02, 000804. Dr. Jenkins “strongly

8 recommended that following his stay at Outback, [J.G.] go on to a longer-term

9 residential therapeutic program, such as a therapeutic boarding school or boarding

10 school with collaborative supports, that can continue addressing each of the above

11 issues in depth.” Id. at 000802. Dr. Jenkins further noted that “[J.G.] remain[ed] at

12 heightened risk of emotional and behavioral dysregulation outside a structured

13 treatment setting.” Id.

14 On or around May 11, 2020, J.G. was admitted to Catalyst Residential

15 Treatment Center (“Catalyst”), a residential treatment center and boarding school

16 located in Utah.7 On May 14, 2020, Meghan Kunz (“NP Kunz”), PMHNP

17

18 visor mirror,” and “would thrash and punch the interior of the car when agitated,

making driving with him incredibly dangerous for the whole family.” DGA_FG

19 000042–43, 000388–94 (photographic evidence). Plaintiff additionally reported that

20 “[J.G.] stole a large sum of money from [them] on at least two occasions,” “[J.G.]

began leaving home for weeks at a time,” “[h]is drug use was also escalating and he

21 made plans to fake drug tests,” “[h]is anxiety, depression, and substance abuse had

22 gotten so out of control that [their] home environment was no longer safe, and his

ability to regulate his emotions had completely dissipated,” and “[his] anger and

23 aggression had gotten so dire, that there were numerous times [they considered]

24 calling the police.” Id.

7 The precise date of J.G.’s admission to Catalyst is unclear from the evidence in the

25

record. J.G. was discharged from Outback on May 11, 2020. DGA_FG 000043. NP

26 Kunz’s psychological medical evaluation states J.G. came to Catalyst directly from

Outback, but lists an admission date of “2/11/2020”—which would have been three

27

months before he was discharged from Outback. Id. at 000820, 000824. Other

28

1 (Psychiatric Mental Health Nurse Practitioner) conducted a psychiatric medication

2 evaluation of J.G. Id. at 000823. NP Kunz concurred with Dr. Jenkins’ diagnoses and

3 recommended the following pharmacological interventions:

4 MEDICATIONS: No medications will be started at this time.

5 Rationale/ Counseling/ Education Risk vs. Benefit: I highly

recommend this program for the individual, family, group, and

6

recreational therapy. The academic and Substance use treatment that

7 is offered here at this program will benefit him greatly. Catalyst will

also allow him to work on his emotional regulation, coping skills,

8

cognitive and behavioral issues, and solution focused motives as well

9 as other treatment approaches.

10 Id. J.G. remained at Catalyst for treatment from the date of his admission until he was

11 discharged on June 4, 2021. Id. at 000949.

12 III. Denial of Benefits and Appeals

13 In or around May 2020, Anthem received a coverage request for residential

14 psychiatric care at Catalyst for the seven day-period beginning May 15, 2020, which

15 Anthem approved as “medically necessary under [Plaintiff’s] benefit plan.” DGA_FG

16 000009–11. On May 22, 2020, Anthem approved an extension request for an

17 additional 7 days of residential psychiatric care, beginning May 22, 2020. Id. On

18

19 records from Catalyst state J.G. was admitted on “05/11/2019.” Id. at 000949.

20 Defendant, in turn, contends J.G. was admitted on May 15, 2020, which was the first

date of service Plaintiff requested and Anthem approved. Dkt. 86 (Def. Opening Trial

21 Br.) at 7; DGA_FG 000001, 000009–18; ANTHEM_FREDG002582.

22 Based on the evidence submitted, the court finds: (1) J.G. was admitted to Catalyst on

or around May 11, 2020; (2) Plaintiff requested approval of residential treatment

23

beginning on or around May 15, 2020; and (3) any conflicting dates reflect

24 typographical errors. The record indicates J.G. was discharged from Outback on May

11, 2020, and admitted to Catalyst directly. DGA_FG 000820, 000824. Furthermore,

25

the dates listed in Catalyst’s records, “05/11/2019” and “2/11/2020,” differ from May

26 11, 2020 (5/11/2020) by one year and one key on a keyboard number pad

respectively—suggesting typographical errors. Regardless, the precise date of J.G.’s

27

admission to Catalyst is not material to the court’s ultimate findings of fact and

28 conclusions of law.

1 June 4, 2020, Anthem approved an additional 4 days of residential psychiatric care as

2 “medically necessary under [Plaintiff’s] benefit plan,” while denying 3 days of

3 requested care as “Not Medically Necessary.” Id. at 000012–17.

4 The denial letter states the claim was reviewed by David Naimark, M.D. (“Dr.

5 Naimark”), using the “MCG guideline Residential Behavioral Health Level of Care,

6 Child or Adolescent (ORG: B-902-RES)” (the “MCG Guidelines”). Id. at 000016–17;

7 see also ANTHEM_FREDG000817–22. The denial letter and Dr. Naimark’s notes

8 offered the following rationale for the denial decision:

9 The plan clinical criteria considers ongoing residential treatment

medically necessary for those who are a danger to themselves or

10

others (as shown by hearing voices telling them to harm themselves or

11 others or persistent thoughts of harm that cannot be managed at a

lower level of care). This service can also be medically necessary for

12

those who have a mental health condition that is causing serious

13 problems with functioning. (For example, being impulsive or

abusive, very poor self care, not sleeping or eating, avoidance of

14

personal interactions, or unable to perform usual obligations). In

15 addition, the person must be willing to stay and participate, and is

expected to either improve with this care, or to keep from getting

16

worse. The information we have does not show your condition is

17 likely to further improve with this care or get worse without it. For

this reason, the request is denied as not medically necessary. There

18

may be other treatment options to help you, such as outpatient

19 services. You may want to discuss these with your doctor. It may

help your doctor to know we reviewed the request using the MCG

20

guideline Residential Behavioral Health Level of Care, Child or

21 Adolescent (ORG: B-902-RES).

22 DGA_FG 000016; ANTHEM_FREDG000821.

23 Plaintiff submitted a level one appeal to Anthem along with supporting

24 documentation including: an appeal letter, 384 pages of medical records from

25 Outback, 21 pages of medical records from Catalyst, Dr. Jenkins’ psychological

26 assessment report, and letters of medical necessity. DGA_FG 000023–25. The Plan

27 forwarded the appeal and supporting documentation to Anthem on February 2 through

28 4, 2021, id. at 000837–40, and Kayla Fisher, M.D. (“Dr. Fisher”) conducted the

1 review, ANTHEM_FREDG000814–16.

2 Anthem upheld the denial decision in a letter, dated March 11, 2021, which

3 stated in relevant part:

4 We reviewed all the information that was given to us before with the

first request for coverage. We also reviewed all that was given to us

5

for the appeal. Your doctor wanted you to stay longer in residential

6 treatment center care. You were getting this because you had been at

risk for serious harm without 24 hour care. We understand that you

7

would like us to change our first decision. Now we have new

8 information from the medical record plus letters. We still do not think

this is medically necessary for you. We believe our first decision is

9

correct for the following reason: after the treatment you had, you were

10 no longer at risk for serious harm that needed 24 hour care. You

could have been treated with outpatient services. We based this

11

decision on the MCG guideline Residential Behavioral Health Level

12 of Care, Child or Adolescent (ORG: B-902-RES).

13 DGA_FG 000847–48.

14 On April 20, 2021, the Plan requested MRI review the level one appeal and all

15 clinical documentation received to date, and answer whether the services were

16 medically necessary as defined by the Plan. Id. at 000854–55. James Kimball, M.D.

17 (“Dr. Kimball”) conducted the review using the following medical guidelines in his

18 rationale: (1) the American Academy of Child and Adolescent Psychiatry, American

19 Association of Community Psychiatrists, Child and Adolescent Level of Care

20 Utilization System, Child and Adolescent Version 20, July 2019 (“CALOCUS”); and

21 (2) the Child and Adolescent Service Intensity Instrument, American Academy of

22 Child and Adolescent Psychiatry, September 2018 (“CASII”). Id. at 000860–61.

23 In a report, dated April 26, 2021, Dr. Kimball opined:

24 The psychiatric residential treatment from 06/02/20 to discharge is not

25 considered medically necessary in accordance with the Plan definition

of medical necessity.

26

The notes indicate that the patient has a complicated psychiatric

27 history. He has a long history of aggression and anger towards family

members. He had been acting out at home and using substances. He

28

1 hHaes wa ahsi sitno ray w oifl dseigrnneifsisc acnatm opu tfproamtie nFte btrreuaatrmye 2n0t 2w0i tthh rmouingihm Mala rye s2u0l2ts0. ,

2 which appears to have helped the patient. He was admitted to a

residential treatment facility on 05/11/20.

3

Unfortunately, it appears that very few clinical notes from the

4

residential facility have been provided for review. There are brief

5 notes from 10/16/20, 09/29/20 which seemed to indicate the patient’s

participation in an activity. There are therapy notes from 05/15/20,

6

05/18/20, 05/21/20 and 05/25/20. Nursing notes were provided from

7 05/15/20. There was also a medication evaluation from 05/15/20. No

other notes were provided from the residential treatment facility,

8

including an initial history and physical.

9

The notes indicate that the patient is at some risk of harm, moderate

10 functional impairment, significant comorbidity, moderately stressful

environment, limited support in the environment, moderate response

11

to treatment, and incompletely engaged. As such, per the Child and

12 Adolescent Level of Care Utilization System for Psychiatric and

Addiction Services, coverage of continued residential level of care has

13

not been met. It is not clear why the patient cannot be managed at a

14 lower level of care.

15 Given that residential level of care was not the most cost efficient

treatment, service or supply than can be safely provided at the most

16

cost efficient and medically appropriate site and level of service, the

17 plan language of medically necessary has not been met.

18 Id. at 000861. The Plan notified Plaintiff by letter, dated May 11, 2021, that the

19 appeal was denied and that he could submit a further appeal. Id. at 000865–67.

20 On September 3, 2021, Plaintiff submitted a level two appeal along with

21 supporting documentation including: an appeal letter, a copy of Plaintiff’s prior

22 appeal, and 246 pages of additional records from Catalyst for the period between June

23 2, 2020 through June 4, 2021. Id. at 000885–1200. On September 28, 2021, the Plan

24 sent the second-level appeal and all submitted medical records to MRI for medical

25 necessity review, which was again conducted by Dr. Kimball. Id. at 001209–15. In a

26 report, dated October 4, 2021, Dr. Kimball opined again that continued residential

27 treatment was not medically necessary in accordance with the Plan’s definition of the

28 term. Id. at 001213.

1 Dr. Kimball’s report for the level two appeal reproduced many of the sentences

2 and paragraphs from his first report verbatim, and again cited CALOCUS and CASII

3 as the medical guidelines used in the review. Compare id. at 000865–67 with

4 001211–15. Both reports included a “Conflict of Interest Statement,” in which he

5 certified that he: “To the best of his[] knowledge, ha[d] not had any prior involvement

6 in the denial/appeal process for the case, regardless of whether the involvement was

7 on behalf of MRI[] or any other peer review vendor[.]” Id. at 001214.

8 By letter, dated October 7, 2021, the Plan informed Plaintiff that his appeal

9 would be presented to the Benefits Committee of the Board at its next meeting, and

10 that “[t]he Trustees will consider all of the evidence and testimony submitted in

11 support of [Plaintiff’s] appeal, but [Plaintiff would] not be entitled to make an in-

12 person appearance at the meeting.” Id. at 001224.

13 On March 1, 2022, the Benefits Committee denied Plaintiff’s appeal “pursuant

14 to Health Plan rules and determinations by Anthem and MRI confirming that the

15 residential treatment [was] not medically necessary as defined by the Health Plan.”

16 Id. at 001235–36. In its supplemental response to Plaintiff’s Interrogatory No. 7,

17 Defendant admitted that, “for mental health claims, [the Plan’s chief medical advisor,

18 Dr. Steven M. Simons,] and the Benefits Committee rely upon the medical specialties

19 of Anthem and MRI’s reviewing physicians to support the claim reasoning[.]” Dkt.

20 68-2 at 13.

21 CONCLUSIONS OF LAW

22 I. Standard of Review for Denial of Benefits

23 As a threshold matter, the parties debate the standard of review applicable to

24 this matter. “A denial of benefits challenged under § 1132(a)(1)(B) is to be reviewed

25 under a de novo standard unless the benefit plan gives the administrator or fiduciary

26 discretionary authority to determine eligibility for benefits or to construe the terms of

27 the plan.” Firestone Tire and Rubber Co. v. Bruch, 489 U.S. 101, 115 (1989). “[F]or

28 a plan to alter the standard of review from the default of de novo to the more lenient

1 abuse of discretion, the plan must unambiguously provide discretion to the

2 administrator.” Abatie v. Alta Health & Life Ins. Co., 458 F.3d 955, 963 (9th Cir.

3 2006) (en banc) (citing Kearney, 175 F.3d at 1090). “ERISA plans are insufficient to

4 confer discretionary authority on the administrator when they do not grant any power

5 to construe the terms of the plan.” Id. at 964.

6 Since Anthem has been dismissed from the action already, the court focuses

7 solely on whether the Benefits Committee possessed the requisite discretionary

8 authority to warrant an abuse of discretion standard of review. See Dkt. 86 at 13 n. 4;

9 Dkt. 87 at 13. The Trust Agreement expressly gives the Board of Trustees the

10 authority to determine eligibility for benefits and to construe and/or interpret the terms

11 of the Plan. DGA_FG 001261–62. Although the Trust Agreement allows the Board

12 of Trustees to allocate and delegate responsibilities to committees and subcommittees

13 of the Board, including the authority to take final action in specified areas, any such

14 allocation or delegation must be in writing and “by resolution duly adopted.” Id. at

15 001263, 001265.

16 Defendant does not identify any separate resolution, writing, or evidence that

17 clearly establishes the Board vested the Benefits Committee with the requisite

18 discretionary authority, and admitted at trial that there is no evidence of such a

19 resolution in the record. Accordingly, the court finds the Board of Trustees did not

20 delegate its discretionary authority to the Board’s Benefits Committee

21 unambiguously, and that the denial of benefits is subject to de novo review.8 See Dan

22 C. v. Anthem Blue Cross Life and Health Ins. Co., No. 24-3203, 2025 WL 1554927, at

23 *1 (9th Cir. June 2, 2025) (affirming trial court’s ruling that the Plan’s denial of

24

25

8 Although the court finds de novo review applies here, the court’s ultimate

26 determinations remain the same under discretionary review, as the court finds below

that Defendant deprived Plaintiff of the opportunities to engage in “meaningful

27

dialogue” on the issue of medical necessity and receive a “full and fair” review of the

28 denial of his claim.

1 continued residential treatment is subject to de novo review, in a parallel action

2 involving the same claims and similar facts).9

3 II. Denial of Benefits

4 A. Medical Necessity

5 Plaintiff has met his burden to prove the residential treatment at issue was

6 medically necessary with credible, persuasive evidence. Anthem determined J.G.’s

7 admission to residential psychiatric care was medically necessary when it approved

8 his initial request for such care. DGA_FG 000009 (“This approval means that, based

9 on the information given to us, the service is considered medically necessary under

10 your benefit plan”). The medical necessity of J.G.’s admission is also established by

11 evidence in the record, including independent assessments by Dr. Jenkins (id. at

12 000786–804), NP Kunz (id. at 000820–23), and Dr. Naimark

13 (ANTHEM_FREDG000816), as well as Plaintiff’s letters of medical necessity

14 (DGA_FG 000828–35).10 Accordingly, the court must determine whether (a) J.G.’s

15

16

9 The Ninth Circuit additionally recognized that “[t]hough the Plan delegates the task

of ‘determining claims appeals’ to the Committee and provides that the Committee

17 ‘will have discretion to deny or grant the appeal in whole or part,’ this language falls

18 short of the unambiguous delegation contemplated by [Ninth Circuit] precedent.”

Dan C., 2025 WL 1554927, at *1 (citing Ingram v. Martin Marietta Long Term

19 Disability Income Plan, 244 F.3d 1109, 1112–13 (9th Cir. 2001)).

20 10 E.g., DGA_FG at 000802 (Dr. Jenkins’ assessment report, dated March 11, 2020:

“It is strongly recommended that following his stay at Outback, [J.G.] go on to a

21

longer-term residential therapeutic program, such as a therapeutic boarding school or

22 boarding school with collaborative supports, that can continue addressing each of [the

diagnosed] issues in depth.”); id. at 820 (NP Kunz’s psychiatric medication

23

evaluation, dated May 14, 2020: “I highly recommend [Catalyst’s] program for the

24 individual, family, group, and recreational therapy. … Catalyst will also allow him to

work on his emotional regulation, coping skills, cognitive and behavioral issues, and

25

solution focused motives as well as other treatment approaches.”); id. at 000829 (letter

26 by Heather Lin, M.D., dated July 20, 2020: “Given the lack of sustainable

improvement with outpatient treatment modalities and deterioration in [J.G.’s]

27

behavior, a higher level of care was recommended for [J.G.] and referral to

28

1 continued residential treatment was medically necessary, or (b) J.G. satisfied the

2 requirements for discharge from residential care.

3 Once a patient has been admitted to residential care under the MCG Guidelines,

4 continued residential care is “generally needed” until one of the following two

5 situation applies:

6 o Residential care is no longer necessary due to adequate patient

stabilization or improvement as indicated by ALL of the

7

following:

8  Risk status acceptable as indicated by ALL of the following:

9  Danger to self or others manageable….

10  Patient and supports understand follow-up treatment and

crisis plan.

11

 Provider and supports are sufficiently available at lower

12 level of care.

13  Patient, as appropriate, can participate as needed in

monitoring at available lower level of care.

14

 Functional status acceptable as indicated by 1 or more of the

15 following:

 No essential function is significantly impaired.

16

 An essential function is impaired, but impairment is

17

manageable at available lower level of care.

18  Medical needs absent or manageable at available lower level of

care as indicated by ALL of the following:

19

 Adverse medication effects absent or manageable

20

 Medical comorbidity absent or manageable …

21

 Medical complications absent or manageable

22  Treatment goals for level of care met.

23 / / /

24

educational consultant/ placement specialist Randi Klein was provided to the family to

25

help guide them towards the appropriate residential treatment facilities”); id. at

26 000831 (letter by Randi Klein, MS, LMFT, LPCC, dated July 7, 2020: “I

recommended that J.G. attend Outback Therapeutic Expeditions. After this program,

27

the treatment team, including myself, recommended that [J.G.] attend[] a residential

28 treatment facility … called Catalyst Residential Treatment Center in Utah.”).

1 o fRoellsoidweinntgia: l care is no longer necessary due to 1 or more of the

2  Higher level of care is indicated (eg, patient condition has

3 deteriorated or more intensive supervision is necessary to

address clinical needs).

4

 Lack of improvement indicates need for long-term custodial

5 facility.

6  Patient or guardian refuses treatment.

7 DGA_FG 000072–73 (emphasis in original, footnotes and references omitted).

8 Anthem’s denial letter, dated June 4, 2020, and Dr. Naimark’s notes offered the

9 following rationale in support of the denial decision:

10 The plan clinical criteria considers ongoing residential treatment

medically necessary for those who are a danger to themselves or

11

others…. This service can also be medically necessary for those who

12 have a mental health condition that is causing serious problems with

functioning. … In addition, the person must be willing to stay and

13

participate, and is expected to either improve with this care, or to keep

14 from getting worse. The information we have does not show your

condition is likely to further improve with this care or get worse

15

without it. For this reason, the request is denied as not medically

16 necessary.

17 DGA_FG 000016; ANTHEM_FREDG000821.

18 Dr. Naimark did not state continued residential care was no longer necessary

19 due to adequate patient stabilization or improvement, or discuss how J.G. met the

20 factors for discharge on this basis.11 See ANTHEM_FREDG 000817–22. To the

21

22 11 Defendant contends “the Plan’s decision, based on informed medical reviews, was

correct because J.G. posed no harm to himself or others justifying 24/7 residential

23

treatment care.” Dkt. 86 at 1. That, however, is not the standard for discharge from

24 residential treatment under the MCG Guidelines. DGA_FG 000072–73. Although

Defendant’s stated justification could potentially support denial of care under the

25

Admission Guidelines of the MCG Guidelines, see id. at 000072, Defendant provides

26 no evidence or legal authority to establish that residential treatment is no longer

medically necessary under the MCG Guidelines and an admitted patient should be

27

discharged once the patient’s clinical status has improved to the point that the patient

28

1 contrary, Dr. Naimark noted J.G.’s chart indicated he had a very chronic diagnosis of

2 oppositional defiant disorder and would not be expected to improve with a short-term

3 intervention, and that the treatment “[was] expected to be a long term placement of

4 180 days.” Id. at 000822. This should have resulted in a determination that discharge

5 based on adequate patient stabilization or improvement was not warranted, and

6 continued residential treatment was medically necessary, because J.G.’s medical needs

7 were not manageable at an available lower level of care.12 See DGA_FG 000073.13

8 Dr. Fisher’s assessment on the level one appeal, ANTHEM_FREDG000815–

9 16, likewise, does not support discharge under the MCG Guidelines, as Dr. Fisher

10 agreed with and relied on Dr. Naimark’s analysis without discussing how this analysis

11 was consistent with the MCG Guidelines for discharging a patient due to adequate

12 patient stabilization or improvement. Accordingly, the court finds neither Dr.

13

14

would no longer qualify for admission. Defendant, thus, fails to establish J.G.’s

15 continued residential care was no longer medically necessary on this basis.

16

12 In particular, neither Dr. Naimark nor Dr. Fisher found, or identified any evidence

to support a finding, that J.G.’s medical comorbidity and substance-related disorder

17 became absent or manageable as of June 2, 2020, as would be required to justify

18 discharge under the MCG Guidelines. See DGA_FG 000073. While Defendant notes

Dr. Fisher stated in her report that J.G. “was not using substances while in the

19 program,” Dkt. 92 at 7 (citing ANTHEM_FREDG000815), the fact that J.G. did not

20 use illegal narcotics and other substances while in residential treatment is insufficient

to establish that his “[s]ubstance-related disorder [was] absent or manageable,” when

21 coverage for continued residential treatment was denied.

22 13 Although Dr. Naimark’s analysis could potentially have supported discharge on the

grounds that a “[h]igher level of care [was] indicated” or “[l]ack of improvement

23

indicate[d] need for long-term custodial facility,” see DGA_FG 000073, neither

24 Anthem nor DGA offered this as a basis for the denial of coverage. To the extent

Defendant may argue continued residential treatment was denied on this basis, such

25

denial would constitute a violation of the Plan’s obligations to: “(1) provide adequate

26 notice in writing to [Plaintiff], setting forth the specific reasons for such denial,

written in a manner calculated to be understood by the participant, and (2) afford a

27

reasonable opportunity to [Plaintiff] for a full and fair review … of the decision

28 denying the claim.” 29 U.S.C. § 1133; Dan C., 2025 WL 1554927, at *2.

1 Naimark nor Dr. Fisher’s reports are sufficient to establish lack of medical necessity

2 or justify Anthem and the Plan’s denial of coverage for continued residential care.

3 Defendant additionally argues its denial decision was appropriate because Dr.

4 Kimball determined independently that “the Plan’s medical necessity standard for

5 continued residential care coverage had not been met and that J.G.’s treatment could

6 have been managed at a lower level of care.” Dkt. 86 at 14. Dr. Kimball, however,

7 did not evaluate J.G.’s continued treatment under the MCG Guidelines and relied

8 instead on CALOCUS and CASII—neither of which were included in the

9 administrative record. While the parties have submitted a copy of the CALOCUS

10 manual for the court’s review, Dkt. 69-2, they have not provided the court with the

11 CASII guidelines. Dr. Kimball’s expert opinions, thus, lack adequate foundation and

12 are inadmissible. See Daubert v. Merrell Dow Pharms., Inc., 509 U.S. 579, 592

13 (1993).

14 Even if the court were to consider Dr. Kimball’s opinion based on the

15 CALOCUS guidelines alone, Dr. Kimball’s assessment would not constitute a valid

16 basis to deny continued residential treatment as of June 2, 2020, since CALOCUS

17 specifies that patient reviews should not be conducted more often than “every three

18 months for extended care services such as residential treatment facilities.” Dkt. 69-2

19 at 30. As it is undisputed that J.G.’s admittance to residential treatment on or around

20 May 14, 2020 was medically necessary, it was improper for Dr. Kimball to apply

21 CALOCUS to determine whether continued residential care was medically necessary

22 less than three weeks later.

23 Furthermore, Dr. Kimball’s reports clearly indicate his assessments were of

24 J.G.’s conditions as of the date of the reports—after J.G. had received months of

25 residential treatment. See DGA_FG 000853 (discussing J.G.’s treatment notes from

26 Catalyst up to and including October 16, 2020, before concluding: “The notes indicate

27 that the patient is at some risk of harm, moderate functional impairment, significant

28 comorbidity, moderately stressful environment, limited support in the environment,

1 moderate response to treatment, and incompletely engaged”) (emphasis added); id. at

2 001213 (discussing treatment notes up to and including May 25, 2021, before

3 concluding the same).14 Accordingly, these assessments do not support his conclusion

4 that continued residential treatment was not medically necessary as of June 2, 2020,

5 when coverage for continued residential treatment was denied. If anything, Dr.

6 Kimball’s assessments demonstrate J.G.’s residential treatment at Catalyst was

7 successful and resulted in sufficient patient stabilization and improvement to allow

8 him to be treated at a lower level of care by the time of his discharge.

9 Defendant argues Plaintiff’s medical necessity letters have no probative value

10 regarding whether the Plan’s standard for medical necessity was met, because they fail

11

14 Since CALOCUS requires an evaluator to “select the highest score or rating in

12

which at least one of the criteria is met,” Dkt. 69-2, Dr. Kimball’s evaluations would

13 only be consistent with his own discussion of J.G.’s “complicated psychiatric history”

14 if they were of J.G.’s status at the date of the reports, rather than when coverage for

continued residential treatment was denied. For example, dimension V of CALOCUS

15 concerns “Resiliency and Treatment History.” Id. at 17–18. Dr. Kimball noted J.G.

16 had “a history of significant outpatient treatment with minimal results,” DGA_FG

000861, 001212, which is consistent with a finding of poor resiliency and/or response

17 to treatment (rating 4, which includes: “b- Previous treatment has not achieved

18 complete remission of symptoms or optimal control of symptoms even with intensive

and/or repeated exposure to treatment” and “c- Attempts to maintain whatever gains

19 that were attained in intensive treatment have limited success, even for limited time

20 periods or in structured settings”). Dr. Kimball, however, found J.G. had a “moderate

response to treatment” (rating 3, which includes: “b- Previous experience in treatment

21 at low level of intensity has not been successful in relief of symptoms or optimal

22 control of symptoms” and “c- Recovery has been maintained for moderate periods of

time, but only with strong professional or peer supports or in structured settings”).

23 DGA_FG 000861, 001212.

24 Evaluating J.G.’s conduct and mental health history based on his “complicated

psychiatric history” alone, without considering the post-denial treatment notes from

25

Catalyst, would result in a CALOCUS level of care recommendation of level five:

26 medically monitored residence-based services—which is the level of care Plaintiff

requested. See Dkt. 69-2 at 8–38. This assessment is also consistent with Anthem’s

27

initial determination that J.G.’s admission to residential treatment was medically

28 necessary.

1 to address whether J.G.’s treatment at Catalyst was the most appropriate and cost-

2 efficient treatment, service, or supply that could be safely provided, at the most cost-

3 efficient and medically appropriate site and level of service. Dkt. 86 at 15–17.

4 According to Defendant, “[a]lthough many of the clinicians asserted that J.G.’s

5 parents had exhausted all treatment options, none of the treating clinicians considered

6 the option of [intensive outpatient program (‘IOP’)] or [partial hospitalization program

7 (‘PHP’)] care, even on a trial basis, prior to beginning at Outback/Catalyst, or

8 following the initial approved stay at Catalyst.” Id. at 16 (emphasis omitted).

9 Defendant does not offer any argument or explanation why Plaintiff would need

10 to establish IOP or PHP care were not more cost-effective, given that Anthem, itself,

11 found J.G.’s admission to residential treatment at Catalyst was medically necessary

12 under the Plan without any discussion of IOP or PHP care. See DGA_FG 000009.

13 Defendant, likewise, does not identify any medical guidelines that state that a patient

14 that has been admitted to residential treatment should be removed from such treatment

15 after less than three weeks of care and required to participate in IOP or PHP care to

16 receive continued residential treatment. To the contrary, the MCG Guidelines

17 establish that such removal is improper unless the patient satisfies the Discharge

18 Guidelines, and CALOCUS precludes reevaluation before the patient has received

19 three months of care. Defendant’s argument, thus, fails.

20 Accordingly, the court concludes Defendant violated the terms of the Plan by

21 determining J.G.’s continued residential treatment was not medically necessary and

22 denying J.G. coverage for continued residential care. Plaintiff, thus, is entitled to

23 benefits.

24 B. Full and Fair Opportunity for Review

25 The Plan also failed to conform to the claims procedure required by statute and

26 regulation. Under federal law, an ERISA plan must:

27 (1) provide adequate notice in writing to any participant or beneficiary

whose claim for benefits under the plan has been denied, setting forth

28

1 be understood by the participant, and

(2) afford a reasonable opportunity to any participant whose claim for

2

benefits has been denied for a full and fair review by the appropriate

3 named fiduciary of the decision denying the claim.

4 29 U.S.C. § 1133.

5 ERISA requires “a meaningful dialogue between ERISA plan administrators

6 and their beneficiaries.” Booton v. Lockheed Med. Benefit Plan, 110 F.3d 1461, 1463

7 (9th Cir. 1997) (citing 29 C.F.R. 2560.503-1(g)(1) (former subd. (f))). “If benefits are

8 denied in whole or in part, the reason for the denial must be stated in reasonably clear

9 language, with specific reference to the plan provisions that form the basis for the

10 denial; if the plan administrators believe that more information is needed to make a

11 reasoned decision, they must ask for it.” Id.

12 “A plan administrator abuses its discretion if it renders a decision without any

13 explanation, construes provisions of the plan in a way that conflicts with the plain

14 language of the plan, or fails to develop facts necessary to its determination.”

15 Anderson v. Suburban Teamsters of N. Ill. Pension Fund Bd. of Trs., 588 F.3d 641,

16 649 (9th Cir. 2009). “The general rule … is that a court will not allow an ERISA plan

17 administrator to assert a reason for denial of benefits that it had not given during the

18 administrative process.” Harlick v. Blue Shield of Cal., 686 F.3d 699, 719–20 (9th

19 Cir. 2012). “The remedy for an improper denial of benefits due to a procedurally

20 deficient review of a claim is the same as the remedy for an improper denial of

21 benefits due to a substantively incorrect medical necessity determination.” Dan C.,

22 2025 WL 1554927, at *2 n. 2 (citing Salomaa v. Honda Long Term Disability Plan,

23 642 F.3d 666, 680–81 (9th Cir. 2011)).

24 In Dan C., 2025 WL 1554927, at *2, the Ninth Circuit affirmed the lower

25 court’s ruling, in an unrelated action against Anthem and the Plan involving similar

26 facts, that the Plan deprived the plaintiff of a full and fair review due to a

27 “fundamental failure to explain to [the Dan C. plaintiff] that the Plan’s operative

28 definition of medical necessity required attempting lower levels of care—namely, an

1 intensive outpatient program [IOP] or partial hospitalization program [PHP]—before

2 residential treatment.” Although “the Plan’s medical reviewers noted internally that

3 IOP or PHP services would be more appropriate for [the minor] than residential

4 treatment,” subsequent letters from the Plan to the Dan C. plaintiff indicated only that

5 “residential treatment was not medically necessary because [the minor] did not pose a

6 danger to himself or others and did not experience serious problems with daily

7 functioning—and therefore could be treated with ‘outpatient services’ instead.” Id. at

8 *3. Because IOP or PHP were not mentioned to the plaintiff in writing until after the

9 minor’s discharge from the residential treatment facility, the Ninth Circuit held

10 Anthem and the Plan’s “inadequate notice deprived Plaintiff of the opportunity to

11 ‘answer[] in time’ the Plan’s questions about lower levels of care, to engage in

12 ‘meaningful dialogue’ on the issue of medical necessity, and to receive a ‘full and

13 fair’ review of the denial of his claim.” Id. (citing Salomaa, 642 F.3d at 679–80).

14 The denial letter here was nearly identical to the letter in Dan C., and stated:

15 “There may be other treatment options to help you, such as outpatient services,”

16 DGA_FG 000016, without explaining: (1) why J.G.’s prior “significant” outpatient

17 treatments, including at Outback, were insufficient; (2) what program or types of

18 outpatient programs Anthem and the Plan believed J.G. should attempt prior to

19 continued residential treatment;15 (3) why Anthem believed J.G. needed to interrupt

20 his residential treatment to attempt IOP or PHP services before he could receive

21 continued care; (4) why such interruption was medically necessary or appropriate

22 considering Anthem had approved his admission to residential treatment already; (5)

23 how J.G. was logistically or practically supposed to attempt IOP or PHP services to

24

25

15 Here, as in Dan C., 2025 WL 1554927, at *3, neither Anthem nor the Plan

26 mentioned IOP or PHP to Plaintiff in writing until four months after J.G. was

discharged from Catalyst on June 4, 2021. See DGA_FG 001217 (letter denying

27

Plaintiff’s second-level appeal, dated October 7, 2021, stating for the first time that

28 “the most cost effective and efficient modality for the treatment is [PHP].”

1 obtain continued residential treatment, given that he was undergoing the previously

2 approved residential treatment when continued coverage was denied; and/or (6) what

3 evidence and analysis led Dr. Naimark and Anthem to conclude “[r]esidential care

4 [was] no longer necessary due to adequate patient stabilization or improvement” under

5 the MCG Guidelines, such that J.G. could be discharged to a lower level of care.

6 Here, as in Dan C., 2025 WL 1554927, at *2, Defendant’s inadequate notice

7 deprived Plaintiff of the opportunity to “answer[] in time” the Plan’s questions about

8 lower levels of care, engage in “meaningful dialogue” on the issue of medical

9 necessity, and receive a “full and fair” review of the denial of his claim. Defendant’s

10 subsequent letters to Plaintiff were similarly deficient and failed to provide Plaintiff a

11 “full and fair” review. See DGA_FG 000847–52, 000865–72, 001216–23.16

12 The court, therefore, finds Plaintiff’s benefits were improperly denied due to a

13 procedurally deficient review of his claim and that Plaintiff is entitled to benefits on

14 this additional basis.

15 III. Breach of Fiduciary Duty

16 “ERISA also provides a claim for breach of fiduciary duty.” Castillo v. Metro.

17 Life Ins. Co., 970 F.3d 1224, 1228 (9th Cir. 2020). “Just as trust law imposes duties

18 on trustees, ERISA imposes duties on plan fiduciaries.” Id. “A fiduciary, for

19 instance, must ‘discharge his duties with respect to a plan solely in the interest of the

20 participants and beneficiaries and ... with the care, skill, prudence, and diligence ... of

21 a prudent man.” Id. (brackets omitted) (quoting 29 U.S.C. § 1104(a)(1)). “An

22 individual bringing a claim under § 1132(a)(3) may seek ‘appropriate equitable relief,’

23 which refers to ‘those categories of relief’ that, traditionally speaking … were

24

25

16 Notably, the Plan failed to offer any explanation for why MRI reviewed the appeals

26 under CALOCUS and CASII, rather than the MCG Guidelines, see DGA_FG

000865–67, 001216–18, which further deprived Plaintiff of the opportunity to engage

27

in “meaningful dialogue” on the issue of medical necessity and receive a “full and

28 fair” review of his appeals.

1 typically available in equity.” Id. at 1229 (cleaned up) (quoting CIGNA Corp. v.

2 Amara, 563 U.S. 421, 439 (2011)).

3 “Because § 1132(a)(3) acts as a safety net, offering appropriate equitable relief

4 for injuries caused by violations that [ERISA] § 502 does not elsewhere adequately

5 remedy, relief is not available under § 1132(a)(3) where Congress elsewhere provided

6 adequate relief for a beneficiary’s injury.” Id. (cleaned up). “Thus, a claimant may

7 not bring a claim for denial of benefits under § 1132(a)(3) when a claim under

8 § 1132(a)(1)(B) will afford adequate relief.” Id. “Claims under § 1132(a)(1)(B) and

9 § 1132(a)(3), however, may proceed simultaneously so long as there is no double

10 recovery.” Id. (quotation marks and citation omitted).

11 In the First Amended Complaint, Plaintiff seeks equitable relief including an

12 order “enjoining the Plan from using level of care guidelines that fall below

13 reasonable standards in the medical community, either as written or as applied, or

14 both,” in addition to his request to recover the full amount of benefits that were

15 denied. Dkt. 13 ¶ 56. Plaintiff’s Opening Trial Brief requests the court “fashion

16 appropriate relief so that neither Plaintiff nor other DGA plan participants are

17 subjected to such claims handling mis-administration.” Dkt. 87 at 22. Defendant

18 responds that any request for relief on behalf of a non-party is improper because

19 Plaintiff did not bring a class action and has not alleged any basis for third-party

20 standing. Dkt. 92 at 15.

21 Plaintiff did not demonstrate at trial that either he or J.G. are likely to have

22 future claims denied based on the level of care guidelines applied here, or that any

23 form of equitable relief is warranted for non-party Plan participants or beneficiaries.

24 The court, therefore, holds Plaintiff is not entitled to any relief beyond recovery of the

25 benefits due, prejudgment interest, and reasonable attorney’s fees and costs, and that

26 “[equitable] relief is not available [to Plaintiff] under § 1132(a)(3).” See Castillo, 970

27 F.3d at 1229; see also Dan C., 2025 WL 1554927, at *3.

28 / / /

1 CONCLUSION

2 Plaintiff's request to overturn Defendant’s denial of benefits is GRANTED, and

3 | judgment is entered in Plaintiffs favor on his § 1132(a)(1)(B) claim. Plaintiffs

4 | request for additional equitable relief under § 1132(a)(3) is DENIED. Plaintiff may

5 | bring a motion for attorney’s fees and costs as permitted under ERISA, 29 U.S.C.

6 | § 1132(a)(1)(B), (g)(1). Plaintiff shall file a proposed judgment and e-mail a Word

7 | format version directly to the court’s chambers email address within five (5) business

8 | days of the filing of this Order.

9

10 IT IS SO ORDERED.

11

12 | Dated: July 7, 2025

13 FERNANDO L. AENLLE-ROCHA

United States District Judge

14

15S

16

17

18

19

20

21

22

23

24

25

26

27

28

94

This is a copy of a public record, reproduced as it was published. It is not legal advice, and it may not be the version a court would rely on. Check the official source before you cite it.

A word about cookies

We need a few to keep you signed in and the library working. The rest help us see which pages people use and where they get stuck. They stay off unless you say yes.